Medication info
Lometan HCT Tablet 5/40/12.5 Milligrams

Lometan HCT Tablet 5/40/12.5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Genupharm Co., Ltd.
Appearance
Pale yellow round film-coated tablets
Packaging
30 tablets/Alu-Alu[(10 tablets/Alu-Alu × 3)]
Approval status
Active

MFDS item code 202002697 · Approved 2020.04.17 · Insurance code 698004590

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual ingredients (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The amounts of each ingredient are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, treatment should be started at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with the use of this medicine in elderly patients, particularly those aged 75 years and older, patients should be monitored very carefully when this medicine is administered.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Genupharm Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension who have difficulty controlling blood pressure with existing treatments, through the combined therapy of amlodipine and olmesartan medoxomil. It effectively lowers blood pressure, reduces the risk of cardiovascular complications, and helps improve blood flow by dilating blood vessels. This allows for stable management of hypertension and maintenance of healthy blood pressure.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual ingredients (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The amounts of each ingredient are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, treatment should be started at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with the use of this medicine in elderly patients, particularly those aged 75 years and older, patients should be monitored very carefully when this medicine is administered.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy. Therefore, it should be stopped immediately upon confirmation of pregnancy. Patients with an allergy to this medication or its ingredients, those with certain heart, kidney, or liver diseases, pregnant or breastfeeding women, and patients with severe hypotension should not use this medication. Patients with depleted blood volume or sodium may experience symptoms of hypotension at the beginning of treatment, so careful monitoring of their condition is required, and appropriate measures should be taken if symptoms occur. Patients with impaired kidney function or kidney transplant recipients should have their kidney function monitored regularly through blood tests while taking this medication, as changes in kidney function may occur. This medication can also affect patients with impaired liver function, requiring dosage adjustments, and is not recommended for patients with severe liver impairment. Patients with heart valve disease or certain heart conditions, patients with primary aldosteronism, and patients with systemic lupus erythematosus should use this medication with caution. The hydrochlorothiazide component may cause acute angle-closure glaucoma or acute myopia; therefore, if sudden ocular pain or vision changes occur, immediate consultation with a healthcare provider is necessary. This medication may cause dizziness or lightheadedness due to its blood pressure-lowering effect, so caution is advised when driving or operating dangerous machinery. Additionally, while taking this medication, the skin may become sensitive to sunlight, so using sunscreen outdoors and avoiding sun exposure is recommended. There may be interactions with other drugs, so please inform your healthcare provider of any other medications you are taking, especially lithium, non-steroidal anti-inflammatory drugs, and other antihypertensives. In case of overdose, symptoms such as hypotension, palpitations, and bradycardia may appear, necessitating immediate medical attention. Finally, the safety of this medication in children has not been established, and elderly patients are recommended to start at low doses considering renal and liver function.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, irritability, anxiety, mood changes, sleep disorders, orthostatic dizziness, syncope, taste disorders, hypertonicity, sensory decline, paresthesia, peripheral neuropathy, drowsiness, syncope, seizures, loss of appetite, tremors, visual disturbances, decreased tear production, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, distension, indigestion, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, vascular edema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, eruptive pustulosis, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, itching, purpura, angioedema, rashes, recurrence of skin lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasm, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paraplegia, myalgia, bone pain, frequent urination, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, weakness, fatigue, chest pain, fever, influenza-like symptoms, lethargy, apathy, edema, pain, facial edema, increased blood creatinine, increased blood urea, increased blood uric acid, decreased blood potassium, elevated gamma-glutamyltransferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, increased blood creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, labial edema, lethargy, loss of consciousness, eczema, limb pain, mild decrease in mean hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, nosebleed, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute deafness, lymphangitis, choroidal effusion, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture, at a temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pale yellow round film-coated tablets

Package unit

30 tablets/Alu-Alu[(10 tablets/Alu-Alu × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.